EU Approval for ELAHERE® in Ovarian Cancer
AbbVie’s ELAHERE® approved for FRα-positive platinum-resistant ovarian cancer in the EU.
AbbVie has received approval from the European Commission for ELAHERE® (mirvetuximab soravtansine), a targeted treatment for patients with FRα-positive platinum-resistant ovarian cancer. This marks a significant milestone, offering an effective new therapy for patients who have undergone one to three prior treatment regimens.
ELAHERE is the first FRα-directed antibody-drug conjugate (ADC) to be approved in the EU, and its approval is supported by results from the Phase 3 MIRASOL trial. Data showed significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy options.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion